Zoetis Inc. $ZTS Stock Holdings Cut by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 33.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 11,579 shares of the company’s stock after selling 5,913 shares during the period. TD Waterhouse Canada Inc.’s holdings in Zoetis were worth $1,457,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Halbert Hargrove Global Advisors LLC boosted its stake in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares in the last quarter. Global Wealth Strategies & Associates bought a new position in Zoetis during the 4th quarter valued at $25,000. KERR FINANCIAL PLANNING Corp bought a new position in Zoetis during the 3rd quarter valued at $31,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis during the 4th quarter valued at $30,000. Finally, Holos Integrated Wealth LLC acquired a new stake in shares of Zoetis during the 4th quarter valued at $32,000. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of recent research reports. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. BTIG Research reiterated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Citigroup initiated coverage on Zoetis in a research report on Wednesday, April 15th. They set a “buy” rating and a $145.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $152.25.

Zoetis Price Performance

ZTS opened at $116.01 on Friday. The stock has a fifty day moving average of $121.02 and a 200-day moving average of $125.73. The firm has a market capitalization of $48.80 billion, a P/E ratio of 19.27, a PEG ratio of 1.79 and a beta of 0.98. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts forecast that Zoetis Inc. will post 7.02 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s dividend payout ratio is presently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.